Healthcare & Life Sciences
Yukin Therapeutics
France
seed
seed
Stage
1
Investors
About
Yukin Therapeutics develops small molecules that inhibit the non-canonical NF-κB2 pathway to inhibit cancer cell proliferation and modulate the tumour micro-environment.
Explore Yukin Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.